We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
451
Apogee Therapeutics
APGE
$10.1B
– –
-329,000
Closed -$12.9M
APPN icon
452
Appian
APPN
$2.11B
– –
-14,027
Closed -$433K
APTV icon
453
Aptiv
APTV
$12.3B
– –
-5,980
Closed -$421K
ARCT icon
454
Arcturus Therapeutics
ARCT
$165M
– –
-39,328
Closed -$958K
ARE icon
455
Alexandria Real Estate Equities
ARE
$9.37B
– –
-3,399
Closed -$398K
ARES icon
456
Ares Management
ARES
$28.1B
– –
-4,175
Closed -$556K
ARIS
457
DELISTED
Aris Water Solutions
ARIS
– –
-55,490
Closed -$870K
ARLO icon
458
Arlo Technologies
ARLO
$1.58B
– –
-14,145
Closed -$184K
AROC icon
459
Archrock
AROC
$6.16B
– –
-60,016
Closed -$1.21M
ATRC icon
460
AtriCure
ATRC
$2.08B
– –
-17,068
Closed -$389K
AVNS
461
DELISTED
Avanos Medical
AVNS
– –
-27,654
Closed -$551K
AVY icon
462
Avery Dennison
AVY
$12.8B
– –
-2,504
Closed -$548K
BAC icon
463
Bank of America
BAC
$429B
– –
-6,029
Closed -$240K
BCSF icon
464
Bain Capital Specialty
BCSF
$821M
– –
-79,569
Closed -$1.3M
BHF icon
465
Brighthouse Financial
BHF
$3.61B
– –
-6,219
Closed -$270K
BLKB icon
466
Blackbaud
BLKB
$1.94B
– –
-4,884
Closed -$372K
BOKF icon
467
BOK Financial
BOKF
$8.58B
– –
-12,026
Closed -$1.1M
BRCC icon
468
BRC Inc
BRCC
$122M
– –
-54,611
Closed -$335K
BRZE icon
469
Braze
BRZE
$3.02B
– –
-7,995
Closed -$311K
BX icon
470
Blackstone
BX
$104B
– –
-7,312
Closed -$905K
CABA icon
471
Cabaletta Bio
CABA
$427M
– –
-464,252
Closed -$3.47M
CAG icon
472
Conagra Brands
CAG
$7.42B
– –
-37,047
Closed -$1.05M
CAT icon
473
Caterpillar
CAT
$361B
– –
-1,954
Closed -$651K
CBT icon
474
Cabot Corp
CBT
$4.72B
– –
-8,914
Closed -$819K
CCAP icon
475
Crescent Capital BDC
CCAP
$405M
– –
-54,357
Closed -$1.02M
17 18
19
20 21

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.